This finding is partially supported by a study that screened 99 primary BC samples by immunohistochemistry analysis using formalin-fixed paraffin-embedded archival tumor tissues confirming that MSLN was only overexpressed in TNBC (67%) in contrast to its rare expression in the hormonal and the HER2+ subtypes (Tchou et al., 2012). Here, ERBB2 is linked to breast cancer.